Intellia Therapeutics, Inc.NTLANASDAQ
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average, modest growth trend.
Left:
||||
Year-over-year research & development expense growth
Latest
7.18%
↓ 87% below average
Average (9y)
54.00%
Historical baseline
Range
High:185.05%
Low:3.59%
CAGR
+6.7%
Consistent expansion
| Period | Value |
|---|---|
| 2024 | 7.18% |
| 2023 | 3.59% |
| 2022 | 82.75% |
| 2021 | 52.79% |
| 2020 | 38.74% |
| 2019 | 21.66% |
| 2018 | 31.74% |
| 2017 | 112.46% |
| 2016 | 185.05% |
| 2015 | 4.00% |